

Andrzej J Jakubowiak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3639557/publications.pdf>

Version: 2024-02-01

111
papers

7,026
citations

117571

34
h-index

60583

81
g-index

112
all docs

112
docs citations

112
times ranked

4653
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciltacabtagene Autoleucl, an Anti-BCMA B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	0.8	160
2	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	0.6	64
3	Knowing the unknowns in high risk multiple myeloma. <i>Blood Reviews</i> , 2022, 51, 100887.	2.8	6
4	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , 2022, 23, 65-76.	5.1	80
5	Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. <i>Oncologist</i> , 2022, 27, e589-e596.	1.9	9
6	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucl in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
7	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. <i>Blood Cancer Journal</i> , 2022, 12, 63.	2.8	5
8	Moving Toward a Cure in Multiple Myeloma: Eradication of Measurable Residual Disease. <i>Advances in Oncology</i> , 2022, 2, 159-169.	0.1	0
9	Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 8014-8014.	0.8	8
10	Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	1
11	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
12	Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 19.	2.8	40
13	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	0.5	10
14	Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). <i>Journal of Clinical Oncology</i> , 2021, 39, 8006-8006.	0.8	33
15	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , 2021, 11, 103.	2.8	32
16	Ciltacabtagene autoleucl, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 8005-8005.	0.8	23
17	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 701-710.	0.2	4
18	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. <i>BMC Cancer</i> , 2021, 21, 659.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Ciltacabtagene autoleucl, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021, 398, 314-324.	6.3	711
20	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , 2021, 138, 2852-2852.	0.6	7
21	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021, 138, 79-79.	0.6	20
22	Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. <i>Blood</i> , 2021, 138, 2723-2723.	0.6	3
23	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 132-141.	6.3	299
24	Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. <i>Blood Cancer Journal</i> , 2020, 10, 80.	2.8	35
25	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , 2020, 9, 889-911.	1.0	101
26	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	0.6	56
27	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020, 136, 936-945.	0.6	436
28	Clinician attitudes and practices toward measurable residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 190, 470-472.	1.2	1
29	Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e543-e546.	0.2	8
30	Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2020, 189, e126-e130.	1.2	13
31	Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. , 2020, 8, e000286.		11
32	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
33	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
34	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , 2020, 37, 1464-1478.	1.3	8
35	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2308-2317.	3.2	20
36	Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 480-489.	0.2	7

#	ARTICLE	IF	CITATIONS
37	Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone. <i>Blood</i> , 2020, 136, 18-20.	0.6	1
38	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020, 136, 45-46.	0.6	19
39	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 26-27.	0.6	6
40	Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8504-8504.	0.8	89
41	Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8513-8513.	0.8	5
42	Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14030-e14030.	0.8	0
43	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. <i>Blood Cancer Journal</i> , 2019, 9, 3.	2.8	39
44	Oprozomib in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 66.	2.8	14
45	Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 186, 549-560.	1.2	58
46	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 4907-4916.	3.2	36
47	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 421-431.	0.6	110
48	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1869-1869.	0.6	36
49	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. <i>Blood</i> , 2019, 134, 859-859.	0.6	18
50	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019, 134, 691-691.	0.6	37
51	Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1876-1876.	0.6	1
52	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
53	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 154-154.	0.6	19
54	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156.	0.6	20

#	ARTICLE	IF	CITATIONS
55	A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma. <i>Blood</i> , 2018, 132, 3229-3229.	0.6	23
56	A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 803-803.	0.6	2
57	Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses. <i>Blood</i> , 2018, 132, 1970-1970.	0.6	2
58	JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE). <i>Blood</i> , 2018, 132, 957-957.	0.6	84
59	Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8002-8002.	0.8	11
60	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8004-8004.	0.8	17
61	Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8031-8031.	0.8	2
62	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. <i>Journal of Clinical Oncology</i> , 2018, 36, e20024-e20024.	0.8	2
63	Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM). <i>Blood</i> , 2018, 132, 3550-3550.	0.6	0
64	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	1.2	58
65	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
66	Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE). <i>Blood</i> , 2017, 130, LBA-4-LBA-4.	0.6	12
67	Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8000-8000.	0.8	30
68	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	0.6	207
69	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
70	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	0.8	70
71	A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 3327-3335.	2.0	29
72	Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2110-2110.	0.6	20

#	ARTICLE	IF	CITATIONS
73	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016, 128, 675-675.	0.6	38
74	Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 973-973.	0.6	10
75	Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8045-8045.	0.8	1
76	Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8021-8021.	0.8	0
77	Comparative Proteomic Profiling of Sera from Patients with Refractory Multiple Myeloma Reveals Pathways and Biomarkers Predicting Response to Bortezomib-Based Therapy. <i>Blood</i> , 2016, 128, 2092-2092.	0.6	1
78	Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. <i>Blood</i> , 2015, 125, 3588-3597.	0.6	104
79	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2959-2961.	0.6	2
80	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1bâ€²2 dose-escalation study. <i>Lancet Haematology</i> , 2015, 2, e516-e527.	2.2	140
81	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	13.9	1,144
82	Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 4223-4223.	0.6	5
83	Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up. <i>Blood</i> , 2015, 126, 510-510.	0.6	16
84	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	0.6	8
85	Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8510-8510.	0.8	9
86	Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8525-8525.	0.8	2
87	A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8573-8573.	0.8	7
88	Comparative Proteomic Profiling of Refractory/Relapsed Multiple Myeloma Patient Plasma Cells Reveals Biomarkers and Pathways Involved in Bortezomib-Based-Therapy Resistance. <i>Blood</i> , 2015, 126, 2986-2986.	0.6	1
89	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. <i>Blood</i> , 2015, 126, 5322-5322.	0.6	0
90	Insulin Growth Factor 1 Receptor (IGF-1R) Inhibitor, Linsitinib (OSI-906) in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Prolife and Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4234-4234.	0.6	0

#	ARTICLE	IF	CITATIONS
91	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014, 123, 1461-1469.	0.6	174
92	Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview. <i>Cancer Treatment Reviews</i> , 2014, 40, 781-790.	3.4	43
93	Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts). <i>Blood</i> , 2014, 124, 2141-2141.	0.6	6
94	Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 279-279.	0.6	3
95	Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 3186-3186.	0.6	9
96	Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2013, 122, 3220-3220.	0.6	12
97	Pilot Study Of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 4607-4607.	0.6	2
98	Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8543-8543.	0.8	10
99	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8588-8588.	0.8	1
100	A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood</i> , 2012, 120, 1801-1809.	0.6	393
101	Novel Therapies for Relapsed/Refractory Multiple Myeloma: How Can We Improve on “Salvage Therapy?” Introduction. <i>Seminars in Hematology</i> , 2012, 49, S1-S2.	1.8	5
102	Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives. <i>Seminars in Hematology</i> , 2012, 49, S16-S32.	1.8	31
103	Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1960-1965.	0.8	184
104	A Phase II Study of Consolidation Treatment with Iodine-131 Tositumomab (Bexxar®, [®]) in Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 1854-1854.	0.6	4
105	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012, 120, 202-202.	0.6	16
106	Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT). <i>Blood</i> , 2012, 120, 4053-4053.	0.6	4
107	A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8020-8020.	0.8	2
108	Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8035-8035.	0.8	1

#	ARTICLE	IF	CITATIONS
109	A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).. Journal of Clinical Oncology, 2012, 30, TPS8114-TPS8114.	0.8	0
110	Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.. Blood, 2012, 120, 2936-2936.	0.6	1
111	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116, 679-686.	0.6	790